1Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol, 2004,88:982-987.
2Blinder KJ,Bradley S,Bressler NM,et al. Effect of lesion size, visual acuity,and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration:TAP and VIP rep
3Eter N,Vogel A,Inhetvin-Hutter C,et al.Interval reduction of photodynamic therapy(PDT)in age-related macular degeneration (AMD)is not advantageous: a pilot project. Ophthalmologe, 2003,100:314-317.
4Kumar A, Prakash G, Singh RP. Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization. Acta Ophthalmol Scand, 2004,82:205-208.
5Farah ME, Cardillo JA, Luzardo AC, et al. Indocyanine green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age related macular degeneration. Br J Ophthalmol, 2004,88:1055-1059.
6Ming Y, Algvere PV, Odergren A.Subthreshold transpupillary thermotherapy reduces experimental choroidal neovascularization in the mouse without collateral damage to the neural retina. Invest Ophthalmol Vis Sci,2004,45:1969-1974.
7Connolly BP, Regillo CD, Eagle RC Jr,et al.The histopathologic effects of transpupillary thermotherapy in human eyes. Ophthalmology, 2003 ,110:415-420.
8Matsuoka KM, Ogata N, Otsuji T, et al. Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy. Br J Ophthalmol, 2004,88:809-815.
2Klein R, Knudtson MD, Lee KE,et al. Age-period-cohort effect on the incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2008;(115):1460-1467.
3Bai ZL, Ren BC, Yang JG,et al.Epidemiological investigation on age-related macular degeneration in rural area of Shanxi Province. China Int J Ophthalmol 2005; 1(1):77-84.
4Assink J, Kaver C, Houwing J, et al. Heterogeneity of the genetic risk in age-related macular disease:a population-based familial risk study. Ophthalmology 2005; 112(3):482.
5Daniel E, Yvette P, Hul J, et al. Age-related maculopathy:a genome wide scan with continued evidence of susceptibility loci within the lq31, 10q26 and 17q25 regions. Am J Hurn Genet 2004; 75(2):174-189.
6Seddon JM, Cote J, Pap WF, et al. The US twin study of age- related macular degeneration:relative roles of genetic and environmental influences. Arch Ophthalmol 2005; 123(3):321.
7Hammond CJ, Wbster AR, Snieder H,et al. Genetic influence on early age-related maculopathy:a twin study. Ophthalmology 2002; 109:730.
8Postel EA, Agarwal A, Schmidt S,et al. Comparing age-related macular families. Am J Ophthalmol 2005; 139(5):820-825.
9Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmology 1998; 116(8):1082-1088.
10Abecasis GR, Yashar BM, Zhao Y,et al. Age-related macular degeneration: a high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. Am J Hum Gene 2004; 74(3):482-494.
